NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price, Forecast & News

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) released its quarterly earnings data on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.06. The specialty pharmaceutical company had revenue of $5.90 million for the quarter, compared to analysts' expectations of $6.55 million. Adamis Pharmaceuticals had a negative return on equity of 90.00% and a negative net margin of 175.77%. View Adamis Pharmaceuticals' Earnings History.

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Adamis Pharmaceuticals.

4 brokers have issued 1 year target prices for Adamis Pharmaceuticals' shares. Their forecasts range from $1.10 to $6.00. On average, they expect Adamis Pharmaceuticals' share price to reach $3.70 in the next twelve months. This suggests a possible upside of 372.7% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamis Pharmaceuticals.

Press coverage about ADMP stock has trended negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Adamis Pharmaceuticals.

Some companies that are related to Adamis Pharmaceuticals include Arbutus Biopharma (ABUS), Ovid Therapeutics (OVID), Nature's Sunshine Products (NATR), Aravive (ARAV), Monopar Therapeutics (MNPR), NuCana (NCNA), Fortress Biotech (FBIO), Kala Pharmaceuticals (KALA), Arcturus Therapeutics (ARCT), Harrow Health (HROW), Mustang Bio (MBIO), Aldeyra Therapeutics (ALDX), Obseva (OBSV), PhaseBio Pharmaceuticals (PHAS) and Galectin Therapeutics (GALT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Trevena (TRVN), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Exelixis (EXEL) and BioDelivery Sciences International (BDSI).

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMP stock can currently be purchased for approximately $0.78.

Adamis Pharmaceuticals has a market capitalization of $48.24 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.

The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com/.

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]